Hikal Share Price Today | Stock Price & Hikal Share Screener

HIKAL Pharmaceuticals
Live Share Price NSE
₹214.45
▼ -3.69 (-1.69%)
2026-10-05 00:00:00
Live Share Price BSE
₹214.45
▼ -3.70 (-1.70%)
2026-10-05 00:00:00

As of October 5, 2026, the live Hikal share price (NSE: HIKAL) is ₹214.45 on NSE and ₹214.45 on BSE, down 1.69% from the previous close, with shares trading between ₹213.28 and ₹221.35 in today's trading session, and a 52-week range of ₹147.08–₹256.15. Check Hikal 52-week for the annual price range and momentum. Use the Hikal stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Hikal opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹411 and net income of ₹-7, with EBITDA of ₹45, an operating margin of 9.0% and a profit margin of -1.7%.

Hikal Market Cap ₹2,689.68 Cr.
HIKAL P/E Ratio (TTM) -79.49
Hikal P/B Ratio 2.24
EPS (TTM) ₹-3.96
Dividend Yield 0.28%
Debt to Equity 0.59
HIKAL 52 Week High ₹256.15
Hikal 52 Week Low ₹147.08
Operating Margin 9.00%
Profit Margin -1.70%
HIKAL Revenue (TTM) ₹411.00
EBITDA ₹45.00
Net Income ₹-7.00
Total Assets ₹2,365.00
Total Equity ₹1,199.00

Hikal Share Price Chart

Track the current stock price of Hikal with an interactive chart. Analyse HIKAL share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Hikal stock quote in one place.

The quote of ₹214.45 sits between the 52-week low of ₹147.08 and the 52-week high of ₹256.15, and the latest session moved -1.69% from the previous close.

Hikal Company Profile - Fundamental Screener

Screen Hikal company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for HIKAL shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE475B01022.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE475B01022

Hikal Balance Sheet Screener

Screen HIKAL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹2,365, down from ₹2,529 in 2025.

Latest statistics put total assets at ₹2,365 and shareholder funds at ₹1,199, with a leverage ratio of 0.59.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 2,365 2,529 2,487 2,386 2,213 1,913 1,768 1,686 1,542 1,380
Current Assets 884 995 967 939 964 879 775 830 690 577
Fixed Assets 1,333 1,365 1,071 948 880 713 735 713 634 668

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 488 477 543 591 376 323 355 327 312 334
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 1,199 1,262 1,188 1,134 1,068 933 817 756 669 605
Share Capital 25 25 25 25 25 25 25 25 16 16
Reserves & Surplus 1,174 1,238 1,163 1,109 1,043 909 792 732 653 589

Hikal Income Statement Screener - Profit & Revenue Analysis

Screen Hikal income statement and profit fundamentals. Analyze HIKAL quarterly results. Hikal reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Jun, revenue was ₹411 and net profit was ₹-7, equal to earnings per unit of ₹-0.60, at an operating margin of 9%.

In that period expenses were ₹366, interest cost ₹15 and tax ₹-3. The next period listed, 2026-Mar, shows revenue of ₹524 and net profit of ₹14.

Item 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar 2022-Dec

Revenue and Expenses

Revenue 411 524 494 318 372 551 443 451 404 513 439 432 387 538 541
Expenses 366 461 450 311 355 429 376 378 349 420 383 377 338 457 466

Operating Costs and Margins

EBITDA 45 63 44 7 17 122 67 73 56 94 56 55 49 81 75
Operating Profit % 9.00% 11.00% 8.00% 2.00% 4.00% 22.00% 14.00% 16.00% 14.00% 18.00% 13.00% 12.00% 13.00% 15.00% 14.00%
Depreciation 43 42 41 41 39 38 33 32 32 32 29 29 28 27 28
Interest 15 15 16 15 17 18 19 19 20 15 14 13 14 13 13

Profit and Earnings

Profit Before Tax -10 8 -9 -47 -30 68 24 25 7 47 22 17 10 49 36
Tax -3 -6 -3 -12 -8 18 7 7 2 13 6 4 3 13 9
Net Profit -7 14 -6 -35 -22 50 17 18 5 34 16 13 7 36 26
EPS -0.60 1.17 -0.48 -2.83 -1.82 4.07 1.39 1.48 0.41 2.76 1.31 1.02 0.56 2.92 2.14

Hikal Cash Flow Screener - Liquidity Fundamentals

Screen HIKAL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹302, and net cash flow was an outflow of ₹3.

Over the same period, investing activities used ₹145 and financing activities used ₹160.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 302 280 187 315 294 229 285 186 139 164
Investing Activities -145 -137 -174 -292 -284 -156 -164 -125 -110 -102

Financing and Net Cash

Financing Activities -160 -144 -27 -8 -6 -97 -101 -55 -25 -63
Net Cash Flow -3 0 -14 15 4 -24 20 6 4 -2

Hikal Shareholding Pattern Screener

See Hikal shareholding pattern with promoter, FII, and DII holdings. Check Hikal promoter holding and ownership changes for HIKAL on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Jun, promoters held 68.85%, foreign institutions 0.99%, domestic institutions 7.24% and the public 17.84%, spread across 73,527 shareholders.

The shareholder count was 73,527 in 2026-Jun, compared with 74,270 in 2026-Mar.

Item 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept

Promoter Holding

Promoter Holding 68.85% 68.85% 68.85% 68.85% 68.85% 68.85% 68.85% 68.85%

Institutional Investors

FII Holding 0.99% 1.43% 2.30% 4.23% 5.36% 5.69% 6.06% 6.78%
DII Holding 7.24% 7.20% 7.05% 5.16% 4.02% 3.80% 3.48% 3.58%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 17.84% 17.18% 16.77% 16.66% 16.75% 16.57% 16.64% 15.81%
Other Holding 5.09% 5.34% 5.02% 5.10% 5.02% 5.08% 4.97% 4.99%
Shareholder Count 73,527 74,270 74,117 73,404 71,391 68,907 71,801 71,912

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Hikal. Hikal dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.60 per unit for 2026-March, a yield of 0.28%, compared with ₹1.40 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.60, ₹1.40 and ₹1.20 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.60 0.28%
2025-March ₹1.40 0.95%
2024-March ₹1.20 0.30%
2023-March ₹1.20 0.45%
2022-March ₹1.60 0.57%
2021-March ₹2.00 0.50%
2020-March ₹1.20 0.84%
2019-March ₹1.20 1.72%
2018-March ₹1.20 0.69%
2017-March ₹1.20 0.87%

Hikal Stock Index Membership - Nifty & Sensex

See which indices include Hikal stock. Check HIKAL index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 5 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP, NIFTY MICROCAP250.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT

Hikal Market Events Screener - Corporate Actions

Get Hikal corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Hikal stock events that may affect HIKAL share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Annual General Meeting dated September 23, 2026, with a record date of September 23, 2026.

It is followed by Dividend dated September 4, 2026 and Quarterly Result Announcement dated August 6, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-09-23 2026-09-23 Annual General Meeting NA 9.35%
2026-09-04 2026-09-04 Dividend ₹ 0.40 /share 10.77%
2026-08-06 2026-08-06 Quarterly Result Announcement NA 5.19%
2026-05-27 2026-05-27 Quarterly Result Announcement NA 6.86%
2026-02-17 2026-02-17 Dividend ₹ 0.20 /share 10.78%
2026-02-11 2026-02-11 Quarterly Result Announcement NA -3.28%
2025-11-13 2025-11-13 Quarterly Result Announcement NA -0.76%
2025-09-23 2025-09-23 Annual General Meeting NA -14.46%
2025-09-02 2025-09-02 Dividend ₹ 0.80 /share -37.12%
2025-08-07 2025-08-07 Quarterly Result Announcement NA -6.81%
2025-05-14 2025-05-14 Quarterly Result Announcement NA 2.48%
2025-02-07 2025-02-08 Dividend ₹ 0.60 /share 5.04%
2025-02-04 2025-02-04 Quarterly Result Announcement NA 6.12%
2024-11-12 2024-11-12 Quarterly Result Announcement NA 1.74%
2024-09-17 2024-09-17 Annual General Meeting NA 17.36%

Hikal Competitors Screener - Peer Stocks Comparison

Screen HIKAL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 432,120 36.04 61,674 12.69% 11,565 36.68
Divis Laboratories 245,532 84.24 11,067 13.95% 2,568 51.70
Torrent Pharmaceuticals 181,333 84.71 13,886 20.34% 2,138 41.12
Zydus Life Science 114,284 25.27 27,658 17.64% 5,026 47.64
Cipla 108,576 32.50 29,045 2.24% 3,870 34.78
Laurus Labs 107,198 98.20 6,868 22.01% 890 58.70
Mankind Pharma 104,707 50.04 14,636 14.85% 1,938 61.75
Dr Reddys Laboratories 100,679 32.41 35,059 3.90% 4,158 53.84
Aurobindo Pharma 96,479 25.84 34,145 5.56% 3,503 50.30
Lupin 92,885 16.82 29,039 26.75% 5,356 31.59

Hikal Company Announcements - News & Reports Screener

Screen HIKAL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 3, 2026.

The next most recent announcements are dated October 3, 2026 and October 3, 2026.

Date Update Actions
2026-10-03 Announcement under Regulation 30 (LODR)-Resignation of Director -
2026-10-03 Announcement under Regulation 30 (LODR)-Change in Management -
2026-10-03 Board Meeting Outcome for Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015- Outcome Of Board Meeting -
2026-10-01 Disclosure Under Regulation 30 Of SEBI (LODR) 2015 - ESG Rating -
2026-09-30 Closure of Trading Window -
2026-09-23 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-09-23 Voting Results Of The 38Th AGM Of The Company. -
2026-09-23 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-23 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-22 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-09-02 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-01 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-31 Letter To Members Pursuant To Regulation 36(1)(B) Of SEBI (LODR) Regulations 2015 -
2026-08-31 Business Responsibility and Sustainability Reporting (BRSR) -
2026-08-31 Reg. 34 (1) Annual Report. -
2026-08-31 Notice Of The 38Th Annual General Meeting Of The Company -
2026-08-27 Communication To Shareholders-Intimation Of Tax Deduction On Dividend. -
2026-08-27 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-26 Date Of AGM Of The Company For FY 2025-26 -
2026-08-26 Announcement under Regulation 30 (LODR)-Change in Management -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹214.45, within a 52-week range of ₹147.08 to ₹256.15. The P/E ratio is -79.49 and the P/B ratio is 2.24, with earnings per unit of ₹-3.96. Market capitalisation stands at ₹2,689.68 Cr and the dividend yield is 0.28%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.